Talphera, Inc. Files 8-K Report

TL;DR

Talphera filed an 8-K, watch for shareholder nominations and other events.

AI Summary

On April 19, 2024, Talphera, Inc. (formerly AcelRx Pharmaceuticals Inc.) filed an 8-K report. The filing indicates that the company is providing information related to shareholder nominations pursuant to Exchange Act Rule 14a-11 and other events. The company is incorporated in Delaware and its principal executive offices are located in San Mateo, California.

Why It Matters

This 8-K filing signals important corporate actions or events, potentially including shareholder nominations, which could impact the company's governance and strategic direction.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant negative or positive financial news.

Key Players & Entities

• Talphera, Inc. (company) — Registrant
• AcelRx Pharmaceuticals Inc (company) — Former company name
• April 19, 2024 (date) — Filing date
• San Mateo, CA (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — ge on which registered Common Stock , $0.001 par value TLPH The Nasdaq Global Mar

Filing Documents

• acrx20240418_8k.htm (8-K) — 25KB
• 0001437749-24-012568.txt ( ) — 154KB
• tlph-20240419.xsd (EX-101.SCH) — 3KB
• tlph-20240419_def.xml (EX-101.DEF) — 11KB
• tlph-20240419_lab.xml (EX-101.LAB) — 15KB
• tlph-20240419_pre.xml (EX-101.PRE) — 11KB
• acrx20240418_8k_htm.xml (XML) — 3KB

08 Shareholder Director Nominations

Item 5.08 Shareholder Director Nominations. The information below under Item 8.01 of this Form 8-K is incorporated by reference into this Item 5.08, to the extent applicable.

01 Other Events

Item 8.01 Other Events. The Board of Directors (the "Board") of Talphera, Inc., a Delaware corporation (the "Company"), has established June 24, 2024 as the date of the Company's 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting"). The time and location of the 2024 Annual Meeting will be set forth in the Company's definitive proxy statement for the 2024 Annual Meeting to be filed with the Securities and Exchange Commission (the "SEC"). The record date for determining stockholders entitled to notice of, and to vote at, the 2024 Annual Meeting will be the close of business on April 26, 2024. Because the date of the 2024 Annual Meeting is being advanced by more than 30 days from the anniversary date of the Company's 2023 Annual Meeting of Stockholders, the Company is filing this Current Report on Form 8-K to inform stockholders of this change and to provide the due date for the submission of any qualified stockholder proposals or qualified stockholder director nominations. Stockholders who intend to present proposals for inclusion in the proxy materials for the 2024 Annual Meeting pursuant to Rule 14a-8 (the "Rule 14a-8") promulgated under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), must ensure that such proposals are received by the Company, in writing, at 1850 Gateway Drive, Suite 175, San Mateo, California 94404, and be directed to the attention of the Corporate Secretary, no later than April 23, 2024, which the Company has determined to be a reasonable time before it expects to begin to deliver and make available its proxy materials, and must furthermore comply with all applicable requirements of Rule 14a-8. Pursuant to the Company's Amended and Restated Bylaws (the "Bylaws"), to be considered timely, stockholders who intend to present proposals for director nominations or any other proposal at the 2024 Annual Meeting must provide notice in writing to the Company at 1850 Gateway Drive, Suite 175, San Mateo, California

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 19, 2024 TALPHERA, INC. By: /s/ Raffi Asadorian Raffi Asadorian Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR